# A Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067

> **NCT01568034** · PHASE2 · COMPLETED · sponsor: **Bial - Portela C S.A.** · enrollment: 10 (actual)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** BIA 9-1067
- **DRUG:** BIA 9-1067
- **DRUG:** BIA 9-1067
- **DRUG:** Placebo
- **DRUG:** Levodopa/Carbidopa
- **DRUG:** Levodopa/Benzerazide

## Key facts

- **NCT ID:** NCT01568034
- **Lead sponsor:** Bial - Portela C S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2010-02
- **Final completion:** 2010-02
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2015-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01568034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01568034, "A Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01568034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*